Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus OTICAIR.
CORTIFOAM vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: 85% unchanged; biliary/fecal: 10%
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid